Compounds > n-methyl-3,4-methylenedioxyamphetamine
Page last updated: 2024-10-21

n-methyl-3,4-methylenedioxyamphetamine and Parkinsonian Disorders

n-methyl-3,4-methylenedioxyamphetamine has been researched along with Parkinsonian Disorders in 13 studies

N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (84.62)29.6817
2010's1 (7.69)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Millot, M1
Saga, Y1
Duperrier, S2
Météreau, E2
Beaudoin-Gobert, M2
Sgambato, V1
Thobois, S1
Tremblay, L1
Sgambato-Faure, V1
Holden, C1
Ricaurte, GA1
Yuan, J1
Hatzidimitriou, G1
Cord, BJ1
McCann, UD1
Carmichael, M1
Mithoefer, M1
Jerome, L1
Doblin, R1
O'Shea, E1
Colado, MI1
Iravani, MM1
Jackson, MJ1
Kuoppamäki, M1
Smith, LA1
Jenner, P1
Cosentino, C1
Lebsanft, HB1
Kohles, T1
Kovar, KA1
Schmidt, WJ1
Leslie, M1
Bishop, C1
Taylor, JL1
Kuhn, DM1
Eskow, KL1
Park, JY1
Walker, PD1
Smith, RM1
Tivarus, M1
Campbell, HL1
Hillier, A1
Beversdorf, DQ1

Other Studies

13 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Parkinsonian Disorders

ArticleYear
Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys.
    Neurobiology of disease, 2020, Volume: 134

    Topics: Animals; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Macaca fascicularis; Mal

2020
Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Diffusion Tensor Imaging; Disease Mode

2018
Neuroscience. Drug find could give ravers the jitters.
    Science (New York, N.Y.), 2002, Sep-27, Volume: 297, Issue:5590

    Topics: Animals; Axons; Brain; Clinical Trials as Topic; Dopamine; Hallucinogens; Haplorhini; Humans; Motor

2002
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
    Science (New York, N.Y.), 2002, 09-27, Volume: 297, Issue:5590

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str

2002
A worry for ravers. One night of ecstasy could cause brain damage.
    Newsweek, 2002, Oct-07, Volume: 140, Issue:15

    Topics: Adolescent; Brain Injuries; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders;

2002
MDMA ("ecstasy") and neurotoxicity.
    Science (New York, N.Y.), 2003, Jun-06, Volume: 300, Issue:5625

    Topics: Animals; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Hallucinogens; Haplorhini; Hu

2003
Is frequent dosing with ecstasy a risky business for dopamine-containing neurons?
    Trends in pharmacological sciences, 2003, Volume: 24, Issue:6

    Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Humans; N-Methyl-3,4-methylenedioxyamphetamine;

2003
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Oct-08, Volume: 23, Issue:27

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli

2003
Ecstasy and acute dystonia.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:11

    Topics: Acute Disease; Adolescent; Adrenergic Uptake Inhibitors; Biperiden; Dose-Response Relationship, Drug

2004
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
    Synapse (New York, N.Y.), 2005, Mar-01, Volume: 55, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio

2005
Up to speed.
    Science of aging knowledge environment : SAGE KE, 2005, Aug-10, Volume: 2005, Issue:32

    Topics: Amphetamines; Animals; Brain; Disease Models, Animal; Mice; N-Methyl-3,4-methylenedioxyamphetamine;

2005
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    The European journal of neuroscience, 2006, Volume: 23, Issue:10

    Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Respons

2006
Apparent transient effects of recent "ecstasy" use on cognitive performance and extrapyramidal signs in human subjects.
    Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2006, Volume: 19, Issue:3

    Topics: Adult; Analysis of Variance; Basal Ganglia Diseases; Blinking; Cognition; Cognition Disorders; Extra

2006